Suppr超能文献

OX40 在体内控制 T 细胞免疫和免疫耐受中的新见解。

New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

机构信息

Transplant Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

出版信息

J Immunol. 2012 Jan 15;188(2):892-901. doi: 10.4049/jimmunol.1101373. Epub 2011 Dec 5.

Abstract

OX40 is a T cell costimulatory molecule that belongs to the TNFR superfamily. In the absence of immune activation, OX40 is selectively expressed by Foxp3(+) regulatory T cells (Tregs), but not by resting conventional T cells. The exact role of OX40 in Treg homeostasis and function remains incompletely defined. In this study, we demonstrate that OX40 engagement in vivo in naive mice induces initial expansion of Foxp3(+) Tregs, but the expanded Tregs have poor suppressive function and exhibit features of exhaustion. We also show that OX40 enables the activation of the Akt and Stat5 pathways in Tregs, resulting in transient proliferation of Tregs and reduced levels of Foxp3 expression. This creates a state of relative IL-2 deficiency in naive mice that further impacts Tregs. This exhausted Treg phenotype can be prevented by exogenous IL-2, as both OX40 and IL-2 agonists drive further expansion of Tregs in vivo. Importantly, Tregs expanded by both OX40 and IL-2 agonists are potent suppressor cells, and in a heart transplant model, they promote long-term allograft survival. Our data reveal a novel role for OX40 in promoting immune tolerance and may have important clinical implications.

摘要

OX40 是一种 T 细胞共刺激分子,属于 TNFR 超家族。在没有免疫激活的情况下,OX40 选择性地表达于 Foxp3(+)调节性 T 细胞(Tregs),而不是静息常规 T 细胞。OX40 在 Treg 稳态和功能中的确切作用尚未完全定义。在本研究中,我们证明了体内 OX40 的交联在幼稚小鼠中诱导初始 Foxp3(+)Treg 的扩增,但扩增的 Treg 具有较差的抑制功能,并表现出衰竭的特征。我们还表明,OX40 使 Akt 和 Stat5 途径在 Tregs 中被激活,导致 Tregs 的短暂增殖和 Foxp3 表达水平降低。这在幼稚小鼠中造成相对的 IL-2 缺乏,进一步影响 Tregs。这种耗尽的 Treg 表型可以通过外源性 IL-2 来预防,因为 OX40 和 IL-2 激动剂都能在体内进一步扩增 Tregs。重要的是,OX40 和 IL-2 激动剂扩增的 Tregs 都是有效的抑制细胞,在心脏移植模型中,它们促进长期同种移植物存活。我们的数据揭示了 OX40 在促进免疫耐受方面的新作用,可能具有重要的临床意义。

相似文献

1
New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.
J Immunol. 2012 Jan 15;188(2):892-901. doi: 10.4049/jimmunol.1101373. Epub 2011 Dec 5.
3
OX40 costimulation turns off Foxp3+ Tregs.
Blood. 2007 Oct 1;110(7):2501-10. doi: 10.1182/blood-2007-01-070748. Epub 2007 Jun 15.
4
OX40 controls functionally different T cell subsets and their resistance to depletion therapy.
J Immunol. 2007 Oct 15;179(8):5584-91. doi: 10.4049/jimmunol.179.8.5584.
5
A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen.
J Immunol. 2013 Aug 1;191(3):1465-75. doi: 10.4049/jimmunol.1300553. Epub 2013 Jul 1.
7
Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses.
J Immunol. 2009 Jan 15;182(2):793-801. doi: 10.4049/jimmunol.182.2.793.
8
Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation.
Blood. 2009 Sep 24;114(13):2639-48. doi: 10.1182/blood-2009-05-220004. Epub 2009 Jul 30.
9
OX40 controls islet allograft tolerance in CD154 deficient mice by regulating FOXP3+ Tregs.
Transplantation. 2008 Jun 15;85(11):1659-62. doi: 10.1097/TP.0b013e3181726987.

引用本文的文献

1
The homeostasis and heterogeneity of regulatory T cells in sepsis.
Burns Trauma. 2025 Jul 15;13:tkaf047. doi: 10.1093/burnst/tkaf047. eCollection 2025.
2
Prognostic value of the co-stimulatory molecule OX40 expression in Extranodal Natural Killer/T-cell Lymphoma.
Ann Med. 2025 Dec;57(1):2550583. doi: 10.1080/07853890.2025.2550583. Epub 2025 Aug 23.
3
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.
Cancer Res Commun. 2024 Aug 1;4(8):2045-2057. doi: 10.1158/2767-9764.CRC-23-0500.
4
Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
Front Immunol. 2024 Feb 21;15:1345838. doi: 10.3389/fimmu.2024.1345838. eCollection 2024.
5
6
The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity.
Cancers (Basel). 2022 Jan 8;14(2):299. doi: 10.3390/cancers14020299.
7
Critical Roles of Balanced T Helper 9 Cells and Regulatory T Cells in Allergic Airway Inflammation and Tumor Immunity.
J Immunol Res. 2021 Mar 1;2021:8816055. doi: 10.1155/2021/8816055. eCollection 2021.
8
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy.
Pharmaceutics. 2020 Jul 14;12(7):663. doi: 10.3390/pharmaceutics12070663.

本文引用的文献

1
OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling.
J Immunol. 2011 Mar 15;186(6):3547-55. doi: 10.4049/jimmunol.1003156. Epub 2011 Feb 2.
3
Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.
J Clin Invest. 2010 Oct;120(10):3629-40. doi: 10.1172/JCI42933. Epub 2010 Sep 20.
4
A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2.
Eur J Immunol. 2010 Oct;40(10):2902-13. doi: 10.1002/eji.201040505.
5
OX40 is required for regulatory T cell-mediated control of colitis.
J Exp Med. 2010 Apr 12;207(4):699-709. doi: 10.1084/jem.20091618. Epub 2010 Apr 5.
6
Control of immunity by the TNFR-related molecule OX40 (CD134).
Annu Rev Immunol. 2010;28:57-78. doi: 10.1146/annurev-immunol-030409-101243.
7
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.
J Immunol. 2009 Oct 15;183(8):4853-7. doi: 10.4049/jimmunol.0901112. Epub 2009 Sep 28.
8
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.
Nat Immunol. 2009 Sep;10(9):1000-7. doi: 10.1038/ni.1774. Epub 2009 Jul 26.
9
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.
Immunity. 2009 Jun 19;30(6):832-44. doi: 10.1016/j.immuni.2009.04.014.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验